$ALG

Alamo Group Q2 net sales rise 7.6 percent to $450.7 million

Alamo Group (ALG) reported Q2 2026 net sales of $450.7 million, up 7.6% from $419.1 million. Net income was $30.9 million and diluted EPS $2.55. Industrial Equipment sales rose 12.8% to $271.6 million, while Vegetation Management rose 0.4% to $179.1 million. Cash was $195.0 million, total debt $262.7 million.

Original reporting
Published Aug 3, 2026, 8:36 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 3, 2026, 9:26 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Alamo Group Q2 net sales rise 7.6 percent to $450.7 million — source image
Decision brief

The 30-second read

$ALGBullishMed
01

Why it matters

The disclosed quarter provides a fresh earnings datapoint (sales, net income, EPS, adjusted metrics) and context on liquidity (cash, debt) and shareholder returns (repurchases and dividends).

02

Market read

Traders can update near-term expectations for ALG into the scheduled earnings call using the reported Q2 financials and capital-return activity.

03

What to watch

The article does not provide guidance or margin detail by division, so traders should watch for commentary on backlog, pricing, and cost trends during the Aug. 4 call.

Relevance 7/10Novelty 7/10Timing: after-hours Aug. 3, ahead of Aug. 4 10:00 a.m. ET earnings call

Background

Quiver FilingTracker summarizes Alamo Group’s Q2 2026 financial results, capital structure, and upcoming earnings call details.

Company-level read

Ticker impact

$ALGBullishMedium confidence
Context

Alamo Group reported Q2 2026 net sales of $450.7 million (+7.6% YoY) and EPS $2.55, plus adjusted EPS $2.82.

Expected impact

Likely modest positive bias into the earnings call, assuming no major guidance surprises beyond the reported quarter.

Evidence & confidence

The article provides concrete quarterly financials (sales, net income, EPS, adjusted EBITDA) and balance-sheet/capital-return details, which traders can use to frame expectations for the upcoming conference call.

Market effects

May modestly influence sentiment for industrial equipment and vegetation management peers by signaling demand resilience and margin/EBITDA conversion.

No specific regional demand signal beyond company-wide results.

Limited global read-through; primarily company-specific earnings information.

Counterpoint

Vegetation Management division sales were nearly flat (+0.4%), so the consolidated growth may not reflect broad-based improvement.

Key entities

  • Alamo Group

    Reported Q2 2026 net sales, earnings, adjusted metrics, cash/debt, and renewed credit facility; will host an earnings call Aug. 4.

Related articles

$ALGMedAI 8/10

Alamo (NYSE:ALG) Delivers Impressive Q2 CY2026

Alamo Group (NYSE:ALG) reported Q2 CY2026 revenue of $450.7 million, up 7.6% year over year, beating Wall Street estimates by about 3%. Non-GAAP adjusted EPS was $2.82, up from $2.57, and 2.9% above consensus. Analysts expect full-year EPS to rise from $9.42 to $11.19 over the next 12 months.

$ALGMed

ALAMO GROUP INC (ALG): Results of Operations and Financial Condition

ALAMO GROUP INC (ALG) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 3 ex991q22026.htm EX-99.1 Document For: Alamo Group Inc. Contact: Kevin Carter VP Finance, Strategy, and Investor Relations 830-372-9544 Financial Relations Board Joe Calabrese 212-827-3772 ALAMO GROUP ANNOUNCES FINANCIAL RESULTS FOR THE SECOND QUARTER 2026 SEGUIN, Texas,

$HCMMedAI 8/10

Why is HUTCHMED stock surging today?

HUTCHMED shares rose nearly 5% to HK$20.14 after the company reported positive topline results from its SAFFRON Phase III trial. The study of savolitinib (Orpathys) plus osimertinib (Tagrisso) in EGFR-mutant NSCLC met co-primary endpoints, improving progression-free and overall survival in patients with high MET overexpression or amplification after osimertinib progression. The move followed recent analyst target cuts.

$BSLMed

BlueScope profit soars 800 per cent as it pivots to shareholder returns

BlueScope reported FY2026 net profit after tax of $802m, up 857% from FY2025, with EBIT of $1.27b. The company attributed the jump to an impairment charge rolling off and said it is shifting from heavy investment to shareholder returns. It declared an unfranked final dividend of 65c and special dividend of 70c per share. Safety and blast furnace upgrade timelines were also discussed.